Table 1. Patient demographic and clinical criteria.
Abbreviations: BCNU, carmustine; SRS, stereotactic radiosurgery; BED, biological effective dose; BEV, bevacizumab.
| Data category | N |
| Patients (n) | 46 |
| Male (%) | 28 (60.9%) |
| Female (%) | 18 (39.1%) |
| Mean age in years (range) | 50.3 (19-81) |
| Extent of first surgical resection | |
| Complete resection (%) | 20 (43.5%) |
| Partial resection (%) | 23 (52.2%) |
| Biopsy (%) | 3 (4.3%) |
| Radiotherapy post-surgery | 46 (100%) |
| Chemotherapy regimen | |
| Temozolomide (%) | 16 (34%) |
| Temozolomide + Bevacizumab (%) | 6 (13%) |
| BCNU (%) | 24 (52%) |
| Median time between initial diagnosis, recurrence, and SRS in months (range) | 10 (1-94) |
| Median prescription dose (Gy) calculated by BED to a single fraction when multiple fractions were delivered using an alpha/beta of 10 | |
| Cone-based SRS, single fraction (range) | 14 (8-20) |
| Infini, single fraction (range) | 15 (10-24) |
| CyberKnife, single/multiple fraction SRS (range) | 16 (15-17) |
| Median tumor volume | |
| Cone-based SRS | 5.6cc (0.2-65.5 cc) |
| Infini | 3.2cc (0.1-64.8 cc) |
| CyberKnife | 36.9cc (6-71 cc) |
| Concurrent/adjuvant BEV and or chemotherapy with SRS | |
| Received concurrent or adjuvant chemotherapy (%) | 15 (32.6%) |
| Did not receive concurrent or adjuvant chemotherapy (%) | 31 (67.3%) |